Article information
Full text is only aviable in PDF
Bibliografía
[1.]
I. Izarzugaza.
El cáncer de pulmón en España.
Revisión epidemiológica. Arch Bronconeumol, 28 (1992), pp. 311-319
[2.]
V. Monge, G. Fernández, J.M. Quintana.
Mortalidad por cáncer en España (1953-1982) Fundación para la epidemiología hospitalaria.
Madrid, (1992),
[4.]
N. Thatcher.
Haematopoietic growth factors and lung cancer treatment.
Thorax, 47 (1992), pp. 119-126
[6.]
M. Miyake, T. Taki, S. Hitomi, et al.
Correlation of expresion of H/Ley/Leb antigens with survival in patients with carcinoma of the lung.
N Engl J Med, 327 (1992), pp. 14-18
[8.]
J.O.S. Bergh.
Gene amplification in human lung cancer.
Am Rev Respir Dis, 142 (1990), pp. 20-26
[9.]
R.J.C. Slebos, S. Rodenhuis.
The molecular genetics of human lung cancer.
Eur Respir J, 2 (1989), pp. 461-469
[10.]
H. Nishio, S. Nakamura, T. Horai, et al.
Clinical and histopatho-logic evaluation of the expression of Ha-ras and fes oncogene products in lung cancer.
Cancer, 69 (1992), pp. 1.130-1.136
[11.]
J.A. Kern, D.A. Schwartz, J.E. Nordberg, et al.
P 184neu expression in human lung adenocarcinomas predicts shortened survival.
Cancer Res, 50 (1990), pp. 5.184-5.187
[12.]
M. Harada, H. Dosaka-Akita, H. Miyamoto, et al.
Prognostic significance of the expression of ras oncogene product in non-small cell lung cancer.
Cancer, 69 (1992), pp. 72-77
[13.]
H. Miyamoto, M. Harada, H. Isobe, et al.
Prognostic value of nuclear DNA content and expression of the ras oncogene product in lung cancer.
Cancer Res, 51 (1991), pp. 6.346-6.350
[14.]
T.P. Mäkelä, K. Mattson, K. Alitalo.
Tumor markers and oncogenes in lung cancer.
Eur J Cancer, 27 (1991), pp. 1.323-1.327
[15.]
D. Casals, C. Cordón-Cardó.
Resistencia a múltiples fármacos Implicaciones biológicas y clínicas.
Med Clin (Barc), 93 (1989), pp. 181-185
[16.]
A.F. Gazdar.
Molecular markers for the diagnosis and prognosis of lung cancer.
Cancer, 69 (1992), pp. 1.592-1.599
[17.]
R.A. Schmidt, V.W. Rusch, S. Piantadosi.
A flow cytometric study of non-small cell lung cancer classified as TI NO.
Cancer, 69 (1992), pp. 78-85
[18.]
P.T. Cagle, C. Langston, A.E. Fraire, et al.
Absence of correlation between nuclear morphometry and survival in stage I non-small lung carcinoma.
Cancer, 69 (1992), pp. 2.454-2.457
[19.]
H. Stevenson, A.F. Gazdar, R. Phelps, et al.
Tumor cell lines established in vitro: an independent prognostic factor for surival in non-small cell lung cancer.
Ann Int Med, 113 (1990), pp. 764-770
[20.]
N. Masuda, M. Fukuoka, K. Matsui, et al.
Establishment of tumor cell lines as an independent prognostic factor for survival time in patients with small-cell lung cancer.
J Natl Cancer Inst, 83 (1991), pp. 1.743-1.748
[21.]
P. Weynants, Y. Humblet, J.L. Canon, et al.
Biology of small cell lung cancer: an overview.
Eur Respir J, 3 (1990), pp. 699-714
[23.]
P. Santabárbara.
Marcadores tumorales en el cáncer broncopulmonar.
Arch Bronconeumol, 24 (1988), pp. 107-109
[24.]
M.S. Tockman, P.K. Gupta, N.J. Pressman, et al.
Considerations in bringing a cancer biomarker to clinical application.
Cancer Res, 52 (1992), pp. 2.711-2.718
[25.]
J.S. Gronowitz, R. Bergstróm, E. Nou, et al.
Clinical and serologic markers of stage and prognosis in small cell lung cancer. A multivariate analysis.
Cancer, 66 (1990), pp. 722-732
[26.]
A. Ruibal.
El antígeno carcinoembrionario Consideraciones actuales.
Med Clin (Barc), 88 (1987), pp. 541-545
[27.]
A. Ruibal Morell.
Estado actual de los marcadores tumorales.
Oncología, 13 (1990), pp. 311-321
[28.]
E. Szklarz, W. Gawlikowski.
Carcinoembryonic antigen (CEA) in the blood serum of patients with bronchogenic carcinoma and selected diseases of the respiratory tract.
Pneumol Pol, 57 (1989), pp. 217-221
[29.]
J. Niklinski, M. Furman, Z. Palynyczko, et al.
Carcinoembryonic antigen, neuron-specific enolase and creatine kinase-BB as tumor markers for carcinoma of the lung.
Neoplasma, 38 (1991), pp. 645-651
[30.]
T. Shinkai, N. Saijo, K. Tominaga, et al.
Serial plasma carcinoembryonic antigen measurement for monitoring patients with advanced lung cancer during chemotherapy.
Cancer, 57 (1986), pp. 1.318-1.323
[31.]
P. Zatloukal, Z. Voslarova, O. Mericka, et al.
Carcinoembryonic antigen in bronchogenic carcinoma.
Neoplasma, 34 (1987), pp. 73-76
[32.]
S. Kakari, E. Stringou, M. Toumbis, et al.
Five tumor markers in lung cancer: significance of total and ”lipid”-bound sialic acid.
Anticancer Res, 11 (1991), pp. 2.107-2.110
[33.]
H. Ueoka, T. Ohnoshi, T. Moritaka, et al.
A statistical analysis of serum Sialyl Lewis X-l (SLX), CEA SCC and NSE levels in patients with lung cancer.
Nippon Kyobu Shikkan Gakkai Zasshi, 29 (1991), pp. 1.022-1.028
[34.]
Y.C. Lee, P.C. Yang, S.H. Kuo, et al.
Tissue polypeptide antigen and carcinoembryonic antigen as tumor markers in lung cancer.
Taiwan I Hsueh Hui Tsa Chih, 90 (1991), pp. 631-636
[35.]
G.F. Buccheri, B. Violante, A.M. Sartoris, D. Ferrigno, A. Curcio, F. Vola.
Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma.
Cancer, 57 (1986), pp. 2.389-2.396
[36.]
T. Rasmuson, G.R. Bjork, L. Damber, et al.
Tumor markers in bronchogenic carcinoma An evaluation of carcinoembryonic antigen, tissue polypeptide antigen, placental alkaline phosphatase and pseudoridine.
Acta Radiol (Oncol), 22 (1983), pp. 209-214
[37.]
M.L. Ellison, D. Lamb, J. Rivett.
Qualitative aspects of CEA output by a human lung carcinoma cell line.
J Natl Cancer Inst, 59 (1977), pp. 309
[38.]
R.H. Goslin, A.T. Skarin, N. Zamchek.
Carcinoembryonic antigen. A useful monitor of therapy of small cell lung cancer.
JAMA, 246 (1981), pp. 2.173-2.176
[39.]
Rapellino M, Pecchio F, Baldi S, et al. CEA in follow up of lung cancer. XVIIth Meeting of the International Society for Onco development of Biology and Medicine. Freiburg, Alemania, 18-22 Septiembre, 1989.
[40.]
Facciolo F, Martelli M, Rendina EA, et al. CEA. TPA: Clinical usefulness in resected NSCLS patients. XVIIth Meeting of the International Society for Oncodevelopment of Biology and Medicine. Freiburg, Alemania, 18-22 Septiembre, 1989.
[41.]
L.E. Broder, A. Primack.
Marker substances in Bronchogenic Carcinoma: A review Lung Cancer.
Clinical diagnosis and treatment, pp. 37-61
[42.]
T.P. Waalkes, M.D. Abelof, K.B. Woo, et al.
Carcinoembryonic antigen for monitoring patients with small cell carcinoma of the during treatment.
Cancer Res, 40 (1980), pp. 4.420-4.427
[43.]
W. Krischke, N. Niederle, J. Schütte, et al.
Is there any clinical relevance of serial determination of serum carcinoembryonic antigen in small cell lung cancer patients?.
Cancer, 62 (1988), pp. 1.348-1.354
[44.]
W. Walop, M. Chrétien, N.C. Colman, et al.
The use of Biomarkers in the predicion of survival in patients with pulmonary carcinoma.
Cancer, 65 (1990), pp. 2.033-2.046
[45.]
M. Hino, H. Ogasawara, A. Yoshii, et al.
Clinical significance of serum carcinoembryonic antigen in small cell lung cancer patients.
Nippon Kyobu Shikkan Gakkai Zasshi, 30 (1992), pp. 278-284
[46.]
M. Hansen, H.H. Hansen.
Tumour markers in the clinical management of patients with small cell lung cancer.
Eur Respir J, 2 (1989), pp. 700-701
[47.]
P.J. Marangos, A.P. Zis, R.L. Clark, et al.
Neuronal and non-neuronal and hybryd form of enolases in brains: Structural, immunological and functional comparison.
Brain Res, 150 (1978), pp. 117-133
[48.]
E.H. Cooper, T.A.W. Splinter, D.A. Brown, et al.
Evaluation of a radioimmunossay for neuron specific enolase in small cell lung cancer.
Br J Cancer, 52 (1985), pp. 333-338
[49.]
A. Ruibal, G. Encabo, J. Genolla, et al.
La enolasa específica neuronal sérica en pacientes afectos de patologías no tumorales.
Rev Esp Oncología, 32 (1985), pp. 183-186
[50.]
O.C. Burghuber, B. Worofka, G. Schernthaner, et al.
Serum neuronspecific enolase is a useful tumor marker for small cell lung cancer.
Cancer, 65 (1990), pp. 1.386-1.390
[51.]
S. Romero, I. Padilla, M. Mauri, et al.
Utilidad diagnóstica de la determinación sérica de la enolas neuroespecífica en el carcinoma bronquial de células pequeñas.
Med Clin (Barc), 95 (1990), pp. 10-14
[52.]
D.K. Carney, P.J. Marangos, D.C. Ihde, et al.
Serum neurospecific enolase: A marker for disease extent and response to therapy of small-cell lung cancer.
Lancet, 1 (1982), pp. 583-585
[53.]
T. Esscher, L. Steinholtz, J. Bergh, et al.
Neuron specific enolase: a useful diagnostic serum marker for small cell carcinoma of the lung.
Thorax, 40 (1985), pp. 85-90
[54.]
E. Mur, M. Navarro, J. Genolla, et al.
Serum neuronspecific enolase levels in lung pathologies Our experiences.
Int J Biol Markers, 2 (1987), pp. 211-212
[55.]
L.G.M. Jorgensen, H.H. Hansen, E.H. Cooper.
Neuron Specific Enolase Carcinoembryonic Antigen and Lactate Dehydrogenase as indicators of disease activity in small cell lung cancer.
Eur J Cancer Clin Oncol, 25 (1989), pp. 123-128
[56.]
P. Weynants, M. Bauduin, F. Majois, et al.
Serum level of neuronspecific enolase: value as tumor marker of microcellular bronchial cancer.
Acta Clin Belg, 44 (1989), pp. 161-168
[57.]
K.R. Liippo, T. Terho.
Concomitant monitoring of serum neuronspecific enolase and cratinine kinase BB in small cell lung cancer.
Acta oncologica, 30 (1991), pp. 321-324
[58.]
Cooper EH. Neuron Specific Enolase. First International Workshop on Tumor Markers. Erice, Italia, 9-11 Marzo, 1989.
[59.]
H.H. Hansen, M. Hansen.
Tumor markers in small cell lung cancer.
Eur J Cancer Clin Oncol, 23 (1987), pp. 1.585-1.587
[60.]
J.L. Viallard, D. Caillaud, B. Kantelip.
Enzymatic determination of serum Neuron-specific enolase in small cell lung cancers.
Chest, 93 (1988), pp. 1.225-1.233
[61.]
T.A.W. Splinter, E.H. Cooper, G.S. Kho, et al.
Neuron-specific enolase as a guide to the treatment of small cell lung cancer.
Eur J Cancer Clin Oncol, 23 (1987), pp. 171-176
[62.]
W. Fischbach, C. Schwarz-Wallrauch, B. Jany.
Neuron-specific enolase and thimidine kinase as an aid to the diagnosis and treatment monitoring of small cell lung cancer.
Cancer, 63 (1989), pp. 1.143-1.149
[63.]
K. Liippo, T. Terho.
Serum neuron-specific enolase and creatinine kinase BB in small cell lung cancer.
Am Rev Respir Dis, 141 (1990),
[64.]
T.A. Splinter, D.N. Carney, M. Teeling, et al.
Neuron-specific enolase can be used as the solé guide to treat small-cell lung cancer patients in common clinical practice.
J Cancer Res Clin Oncol, 115 (1989), pp. 400-401
[65.]
R.W. Gasser, M. Herold, E. Muller-Holzner, et al.
Neuron-specific enolase as a tumor marker in small cell bronchial carcinoma.
Dtsch Med Wochenschr, 113 (1988), pp. 1.708-1.713
[66.]
R.S. Aroney, W.C. Dermody, P. Aldenderfer, et al.
Multiple sequential biomarkers in monitoring patients with carcinoma of the lung.
Cancer Treatment Report, 68 (1984), pp. 859-866
[67.]
E. Nou, L. Steinholtz, J. Bergh, et al.
Neuron-specific enolase as a follow-up marker in small cell bronchial carcinoma.
Cancer, 65 (1990), pp. 1.380-1.385
[68.]
J.R. Hernández.
Marcadores tumorales. Valor diagnóstico y significado pronóstico en el carcinoma broncogénico Tesis doctoral.
Universidad de Oviedo, (1991),
[69.]
E.H. Cooper, T.A.W. Splinter.
Neuron-specific enolase (NSE): A useful marker in small cell lung cancer.
Lung Cancer, 3 (1987), pp. 61-66
[70.]
G. Jaques, G. Bepler, R. Holle, et al.
Prognostic value of pretreatment carcinoembryonic antigen, neuron-specific enolase and creatine kinase-BB levels in sera of patients with small cell lung cancer.
Cancer, 62 (1988), pp. 125-134
[71.]
M. Harding, J. McAllister, G. Hulks, et al.
Neurone specific enolase (NSE) in small cell lung cancer: a tumor marker of pronostic significance?.
Br J Cancer, 61 (1990), pp. 605-607
[72.]
E.D. Rubery, J.F. Doran, R.J. Thompson.
Brain-type creatin kinase BB levels as a potential tumor marker-serum levels measured by radio-immunoassay in 1015 patients with histologically confirmed malignancies.
Eur J Cancer Clin Oncol, 18 (1981), pp. 951-956
[73.]
A. Usui, K. Fujita, M. Imaizumi, et al.
Determination of creatine kinase isozymes in sera and tissues of patients with various lung carcinomas.
Clinica Chimica Acta, 164 (1987), pp. 47-53
[74.]
A.F. Gazdar, M.H. Zweig, D.N. Carney, et al.
Levels of creatine Kinase and its BB isoenzyme in lung cancer specimens and cultures.
Cancer Res, 41 (1981), pp. 2.773-2.777
[75.]
D.N. Carney, M.H. Zweig, D.C. Ihde, et al.
Elevated serum creatine kinase BB levels in patients with small cell lung cancer.
Cancer Res, 44 (1984), pp. 5.399-5.403
[76.]
M. Hansen.
Serum tumor markers in lung cancer.
Scand J Clin Lab Invest, 206 (1991), pp. 93-101
[77.]
A.G. Pedersen, F.W. Bach, N. Nissen, et al.
Creatine kinase BB and beta-2-microglobulin as markers of CNS metastases in patients with small cell lung cancer.
J Clin Oncol, 3 (1985), pp. 1.364-1.375
[78.]
K. Yamaguchi, K. Abe, T. Kameya, et al.
Production and molecular size heterogeneity of immunoreactive gastrin-releasing peptide in fetal and adult lungs and primary lung tumors.
Cancer Res, 43 (1983), pp. 3.932-3.938
[79.]
D.G. Bostwich, K.A. Roth, C.J. Evans, et al.
Gastrin-releasing peptide, a mammalian analog of Bombesin, is present in human neuroendocrine lung tumors.
Am J Pathol, 117 (1984), pp. 195-200
[80.]
J.C. Willey, J.F. Lechner, C.C. Harris.
Bombesin and the C-terminal tetradecapeptide of gastrin-releasing peptide are growth factors for normal human bronchial epithelial cells.
Exp Cell Res, 153 (1984), pp. 245-248
[81.]
K. Maruno, K. Yamaguchi, K. Abe, et al.
Immunoreactive gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma.
Cancer Res, 49 (1989), pp. 629-632
[82.]
G.V. Scagliotti, M. Piani, E. Gatti, et al.
Combined measurements of neuron specific enolase and bombesin/gastrin releasing peptide in lung cancer.
Eur Respir J, 2 (1989), pp. 746-750
[83.]
A.J. Vangsted, T.W. Schwartz.
Production of gastrin-releasing peptide-(18-27) and a stable fragment of its precursor in small cell lung carcinoma cells.
J Clin Endocrinol Metab, 70 (1990), pp. 1.586-1.593
[84.]
J.J. Holst, M. Hansen, E. Bork, et al.
Elevated plasma concentrations of C-flanking gastrin-releasing peptide in small cell lung cancer.
J Clin Oncol, 7 (1989), pp. 1.831-1.838
[85.]
K. Maruno.
Gastrin-releasing peptide as a specific tumor marker in patients with small cell lung carcinoma, compared with neuron-specific enolase.
Nippon Geka Gakkai Zasshi, 91 (1990), pp. 760-765
[86.]
A.G. Pedersen, K.L. Becker, F. Bach, et al.
Cerebrospinal fluid, bombesin and calcitonin in patients with central nervous System metastases from small cell lung cancer.
J Clin Oncol, 4 (1986), pp. 1.620-1.627
[87.]
H. Kato, T. Torigoe.
Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma.
Cancer, 40 (1977), pp. 1.621-1.628
[88.]
W. Ebert, J.T. Johnson.
Tumor markers in the management of squamous cell carcinoma of the head, neck, and lung.
Excerpta Medica Princeton,
[89.]
R. Molina, X. Filella, M.D. Torres, et al.
SCC antigen measured in malignant and nonmalignant diseases.
Clin Chem, 36 (1990), pp. 251-254
[90.]
J. Upham, B. Campbell.
Utility of squamous cell carcinoma antigen (SCC Ag) as a tumor marker in pulmonary malignancy.
Respir Med, 86 (1992), pp. 201-203
[91.]
N. Mino, A. lio, K. Hamamoto.
Availability of tumor-antigen 4 as a marker of squamous cell carcinoma of the lung and other organs.
Cancer, 62 (1988), pp. 730-734
[92.]
S. Hatakeyama, A. Nagai, S. Kioi, et al.
Clinical evaluation of combination assay of tumor markers in primary lung cancer patients.
Nippon Kyobu Shikkan Gakkai Zasshi, 28 (1990), pp. 1.053-1.058
[93.]
J.J. Body, J.P. Sculier, N. Raymakers, et al.
Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer.
Cancer, 65 (1990), pp. 1.552-1.556
[94.]
F. Pecchio, M. Rapellino, E. Ricci, et al.
TA 4-SCC versus CEA sensitivity for lung cancer.
Tumori, 74 (1988), pp. 393-395
[95.]
W. Ebert, B. Leichtweis, P. Drings.
Significance of SCC antigen determinations for diagnosis and follow-up of patients with squamous cell carcinoma of the lung.
Am Rev Respir Dis, 139 (1989), pp. 218
[96.]
M.M. Lau-Wong, D.W.C. Yeung.
Evaluation of an SCC monoclonal radioimmunoassay (RIA) for diagnosis of squamous cell lung carcinoma.
Lung Cancer, 4 (1988),
[97.]
N. Mino-Miyagawa, Y. Kimura, K. Hamamoto.
Tumor-Antigen 4 Its immunohistochemical distribution and tissue and serum concentrations in squamous cell carcinoma of the lung and esophagus.
Cancer, 66 (1990), pp. 1.505-1.512
[98.]
W. Fischbach, T. Meyer, K. Barthel.
Squamous cell carcinoma antigen in the diagnosis and treatment follow-up of oral and facial squamous cell carcinoma.
Cancer, 65 (1990), pp. 1.321-1.324
[99.]
J.R. Hernández, J.M. García, M.A. Martínez, et al.
Antígeno asociado al carcinoma de células escamosas (SCC): un marcador de evolución en las neoplasias bronquiales epidermoides tratadas.
Arch Bronconeumol, 28 (1992),
[100.]
M. González, J. Espinosa, J. Gandara, et al.
Utilidad práctica de los marcadores tumorales serológicos en el carcinoma de pulmón.
Med Clin (Barc), 96 (1991), pp. 707-710
[101.]
G.F. Buccheri, B. Violante, A.M. Sartoris, et al.
Clinical value of a multiple biomarker assay in patients with bronchogenic carcinoma.
Cancer, 57 (1986), pp. 2.389-2.396
[102.]
G.F. Buccheri, D. Ferrigno, A.M. Sartoris, et al.
Tumor markers in bronchogenic carcinoma. Superiority of tissue polypeptide antigen to carcinoembryonic antigen and carbohydrate antigenic determinant 19-9.
Cancer, 60 (1987), pp. 42-50
[103.]
G.F. Buccheri, D. Ferrigno.
Usefulness of tissue polypeptide antigen is staging monitoring, and prognosis of lung cancer.
Chest, 93 (1988), pp. 565-570
[104.]
G.F. Buccheri, D. Ferrigno.
Prognostic value of the tissue poly-peptide antigen in lung Cancer.
Chest, 101 (1992), pp. 1.287-1.292
[105.]
J. Abrams, L.A. Doyle, J. Aisner.
Staging, prognostic factors, and special considerations in small cell lung cancer.
Semin Oncol, 15 (1988), pp. 261-277
[106.]
D. Solter, B.B. Knowles.
Monoclonal antibody defining a stage-specific embryonic antigen (SSEA-1).
Proc Natl Acad Sci U.S.A, 75 (1978), pp. 5.565-5.569
[107.]
M.T. Allende, M.C. Roiz, F. Vizoso, S.L.X. Seric, et al.
levels in patients with non tumoral pathologies Our experience in 189 cases.
Int J Biol Markers, 5 (1990), pp. 153-154
[108.]
T. Shiota, Y. Matsubara, S. Ikeda, et al.
Evaluation of Sialyl SSEA-1 antigen in patients with lung cancer.
Nippon Gan Chiryo Gakkai Shi, 24 (1989), pp. 1.067-1.073
[109.]
J.R. Hernández, J.M. García, M.A. Martínez, S.L.X. Seric, et al.
values en patients with lung tumors (letter).
Int J Biol Markers, 6 (1991), pp. 35-36
[110.]
J.R. Hernández, J.M. García, M.A. Martínez, et al.
Sialyl SSEA-1 (SLX-1) behabiour in lung diseases.
Eur Respir J, 4 (1991),
[111.]
G. Encabo, A. Ruibal, C.A. Serie.
19-9 levels in patients with non tumoral pathologies Our experience in 892 cases.
Bull Cancer, 73 (1986), pp. 256-259
[112.]
Y. Kimura, T. Fujii, K. Hamamoto, et al.
Serum CA 125 level is a good prognostic indicator in lung cancer.
Br J Cancer, 62 (1990), pp. 676-678
[113.]
M. Díez, F.J. Cerdán, M.D. Ortega, et al.
Evaluation of serum CA 125 as a tumor marker in non small cell lung cancer.
Cancer, 67 (1991), pp. 150-154
[114.]
R. Molina, P. Santabárbara, X. Filella, et al.
Relationship of CA 125 and CA 19.9 with lung carcinoma histological subtype: preliminary study.
Int J Biol Markers, 4 (1989), pp. 215-220
[115.]
Y. Mizushima, H. Hirata, S. Izumi, et al.
Clinical significance of the number of positive tumor markers in assisting the diagnosis of lung cáncer with multiple tumor marker assay.
Oncology, 47 (1990), pp. 43-48
[116.]
G. Letanche, I. Ogier, P. Weynants, et al.
Valuer diagnostique du dosage de l’antigéne carbohydrate 19-9 (CA 19-9) chez les patients porteurs de cancer bronchique primitif.
Rev Pneumol Clin, 41 (1985), pp. 314-316
[117.]
G.B. Ratto, G. Capponi, R. De Grandi, et al.
Tumor markers II. Their significance in the follow-up of patients after radical resection of lung neoplasma.
Minerva Chir, 45 (1990), pp. 1.273-1.280
[118.]
M.T. Allende, J.R. Hernández, A. Bianco, et al.
BCM-RIA levels in patients with lung pathologies.
Int J Biol Markers, 6 (1991), pp. 37-38
[119.]
J.R. Hernández, J.M. García, M.A. Martínez, et al.
Utilidad de la mucina del cáncer de mama como marcador del carcinoma broncogénico.
Arch Bronconeumol, 27 (1991),
[120.]
E.H. Cooper, B.J. Rathbone.
Clinical significance of the immuno-metric measurements of hyaluronic acid.
Ann Clin Biochem, 27 (1990), pp. 444-451
[121.]
W. Knudson, C. Biswas, X.Q. Li, et al.
The role and regulation of tumour-associated hyaluronan.
Ciba Found Symp, (1989),
[122.]
J.R. Hernández, J.M. García, M.A. Martínez, et al.
Utilidad del Ácido Hialurónico determinado en suero y lavado broncoal-veolar como marcador tumoral en el carcinoma broncogénico.
Arch Bronconeumol, 27 (1991), pp. 67-68
[123.]
N. Poulakis, A. Sarandakou, D. Rizos, et al.
Soluble Interleukin-2 receptors and other markers in primary lung cancer.
Cancer, 68 (1991), pp. 1.045-1.049
[124.]
K. Yamaguchi, Y. Nishimura, T. Kiyokawa, et al.
Elevated serum levels of soluble interleukin-2 receptors in small cell lung carcinoma.
J Lab Clin Med, 116 (1990), pp. 457-461
[125.]
E. Tisi, P. Lissoni, M. Angeli, et al.
Postoperative increase in soluble interleukin-2 receptors serum levels as predictor for early recurrence in non-small cell lung carcinoma.
Cancer, 69 (1992), pp. 2.458-2.462
[126.]
G. Buccheri, P. Marino, A. Preatoni, et al.
Soluble interleukin 2 receptor in lung cancer An indirect marker of tumor activity?.
Chest, 99 (1991), pp. 1.433-1.437
[127.]
R.E. Sobol, T. O’connor, J. Addison, et al.
Elevated serum chromogranin A concentrations in small cell lung carcinoma.
Ann Intern Med, 105 (1986), pp. 698-700
[128.]
V. Sagman, R. Feld, W.K. Evans, et al.
The prognostic significance of pretreatment serum lactate dehydrogenase in patients with small-cell lung cancer.
J Clin Oncol, 9 (1991), pp. 954-961
[129.]
T. Nakano, N. Iwashashi, J. Maeda, et al.
Serum laminin P1 in small cell lung cancer: a valuable indicator of distant metastasis?.
Br J Cancer, 65 (1992), pp. 608-612
[130.]
V. Abbasciano, L. Graziano, D. Arcudi, et al.
Serum thymidine kinase in diagnosis and follow-up of the small cell carcinoma of the lung.
Med Oncol Tumor Pharmacother, 8 (1991), pp. 29-34
[131.]
C. Lombardi, G.F. Tassi, G. Pizzocolo, et al.
Clinical significance of a multiple biomarker assay in patients with lung cancer.
Chest, 97 (1990), pp. 639-644
[132.]
S.A. Gomm, B.G. Keevil, N. Thatcher, et al.
The valué of tumor markers in lung cancer.
Br J Cancer, 58 (1988), pp. 797-804
[133.]
N. Milman, H. Sengelov, P. Dombernowsky.
Iron status markers in patients with small cell carcinoma of the lung.
Relation to survival. Br J Cancer, 64 (1991), pp. 895-898
[134.]
M. Díez, F.J. Cerdán, M. Arroyo, et al.
Use of the copper/zinc ratio in the diagnosis of lung cancer.
Cancer, 63 (1989), pp. 726-730
[135.]
N. Goldstein, M.L. Lippmann, S.K. Goldberg, et al.
Usefulness of tumor markers in serum and Bronchoalveolar Lavage of patients undergoing Fiberoptic Bronchoscopy.
Am Rev Respir Dis, 132 (1985), pp. 60-64
[136.]
A. De Diego, L. Compte, J. Sanchis, et al.
Usefulness of carcinoembryonic antigen determination in bronchoalveolar lavage fluid. A comparative study among patients with peripheral lugn cancer, pneumonia, and healthy individuals.
Chest, 100 (1991), pp. 1.060-1.063
[137.]
V. Macchia, A. Mariano, M. Cavalcanti, et al.
Tumor markers and lung cancer: Correlation between serum and bronchial secretion levels of CEA, TPA, CanAg CA-50 NSE and ferritin.
Int J Biol Markers, 2 (1987), pp. 151-156
[138.]
M. Clerici, P. Pollice, F. Montinari, et al.
Simultaneous serum and bronchial fluids marker determination in primary lung neoplasms.
J Tumor Marker Oncol, 3/2 (1988), pp. 175-178
[139.]
S.I. Rennard.
Bronchoalveolar lavage in the diagnosis of cancer.
Lung, (1990), pp. 1.035-1.040
[140.]
S.I. Rennard.
Assessment of the clinical value of bronchoalveolar lavage in the diagnosis of cancer in the lung.
Eur Respir Rev, 2 (1992), pp. 100-105
[141.]
A. Ruibal, J. Genollá.
Marcadores tumorales y derrames pleurales.
Med Clin (Barc), 86 (1986), pp. 457-460
[142.]
S. Romero, M. Izquierdo, M. Mauri, et al.
Utilidad diagnóstica de la determinación de la enolasa neuroespecífica en líquido pleural.
Med Clin (Barc), 93 (1989), pp. 568-571
[143.]
P. Ferroni, C. Szpak, J.W. Greiner, et al.
CA 72-4 radioimmunoassay in the diagnosis of malignant effusions Comparison of various tumor markers.
Int J Cancer, 46 (1990), pp. 445-451
[144.]
Y. Niwa, H. Kishimoto, K. Shimokata.
Carcinomatous and tuberculous pleural effusions Comparison of tumor markers.
Chest, 87 (1985), pp. 351-355
[145.]
J. Mezger, M.D. Lamerz, W. Permanetter.
Diagnostic significance of carcinoembrionic antigen in the differencial diagnosis of malignant mesothelioma.
J Thorac Cardiovasc Surg, 100 (1990), pp. 860-866
[146.]
M. Delahaye, H.C. Hoogsteden, T.H. Van der Kwast.
Immunocytochemistry of malignant mesothelioma: OV632 as a marker of malignant mesothelioma.
J Pathol, 165 (1991), pp. 137-143
[147.]
G. Hillerdal, U. Lindqvist, A. Engström-Laurent.
Hyaluronan in pleural effusions and serum.
Cancer, 67 (1991), pp. 2.410-2.414
[148.]
S.E. Bates.
Clinical applications of serum tumor markers.
Ann Intern Med, 115 (1991), pp. 623-638
[149.]
J.S. Lee, W.K. Hong.
Prognostic factors in lung cancer.
N Engl J Med, 327 (1992), pp. 47-48
[150.]
A. López-Encuentra.
La clasificación TNM del carcinoma broncogénico, seis años después.
Arch Bronconeumol, 28 (1992), pp. 360-364
Copyright © 1993. Sociedad Española de Neumología y Cirugía Torácica
